Inventiva announces publication date and presentation of first half 2022 results.

Daix (France), Long Island City (New York, USA)September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), specializing in the clinical development of orally administered small molecules for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases of need Biopharmaceutical company Unsatisfied Medical, today announced that management will announce the company’s financial results for the first half of 2022 in a webcast presentation on Thursday, September 22, 2022.

Inventiva’s first half 2022 results will be announced on Wednesday, September 21, 2022 at 4:00 p.m. (New York) and 10:00 p.m. (Paris).

Conference call, followed by Frederick Krenn, Chairman, CEO and Co-Founder of Inventiva, Pierre Broca, Scientific Director and Co-Founder of Inventiva, and Jean Volatier, Chief Financial Officer of Inventiva , and a question and answer session moderated by Michael Koorman, Medical. Director of Inventiva, will be held in English of Thursday, September 22, 2022 8am (New York), 2pm (Paris).

The conference call and presentation slides can be viewed simultaneously at:
Next : It is also available on the Investors – Financial Results section of the Inventiva website.

Pre-registration is required to receive the access information required to participate in the conference call. From the following link:
Attendees must use the meeting access information (dial-in number and access code) provided in the email received upon registration no later than 10 minutes prior to the meeting start time.

Conference calls and presentations are available online replay After the event, at the address below

About Inventiva

Inventiva is a biopharmaceutical company specializing in the research and development of orally administered small molecules for the treatment of patients with NASH and other unmet medical needs. We have extensive experience and expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic regulation. Inventiva’s most advanced drug candidate, Lanifibranor, is in pivotal Phase 3 NATiV3 clinical trial for the treatment of adult patients with NASH, a common and progressive chronic liver disease with no currently approved therapy It is rated with

The Company has entered into a strategic partnership with AbbVie in the area of ​​autoimmune diseases. This led to the discovery of his RORγ inverse his agonist sedirogant (ABBV-157) for oral administration in adult patients with moderate to severe plaque psoriasis. It is being evaluated in a Phase 2b clinical trial conducted by AbbVie. Inventiva’s portfolio also includes odiparcil, a drug candidate for the treatment of adult patients with mucopolysaccharidosis (MPS) type VI. As part of its decision to focus clinical efforts on ranifibranol development, Inventiva is suspending clinical efforts on his odiparcil and reviewing all available options to optimize its development. Inventiva is selecting oncology drug candidates as part of a program dedicated to the Hippo signaling pathway.

We have a scientific team of approximately 80 people with strong expertise in biology, medical and computational chemistry, pharmacokinetics and pharmacology, and clinical development. Inventiva has a chemical library of approximately 240,000 molecules, of which approximately 60% are proprietary as well as in our own laboratories and equipment.

Inventiva is listed on the Euronext Paris regulated market compartment C (Euronext Paris: IVA – ISIN: FR0013233012) and on the US Nasdaq Global Market (symbol: IVA).

contact address

  • Inventiva – PR – Webcast Invitation H1 2022 – 07 09 2022 – FR

Printable PDF and email

Leave a Comment

Your email address will not be published.